Evidence map›Paper›PMID 39997192›Full record

ArticleMarine drugs2025

Comparative Evaluation of the Antibacterial and Antitumor Activities of Marine Alkaloid 3,10-Dibromofascaplysin.

Maxim E Zhidkov, Polina A Smirnova, Natalia E Grammatikova, Elena B Isakova, Andrey E Shchekotikhin, Olga N Styshova, Anna A Klimovich, Aleksandr M Popov

Abstract readComparative Study
In one paragraph

Article in Marine drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maxim E ZhidkovDepartment of Chemistry and Materials, Institute of High Technologies and Advanced Materials, FEFU Campus, Far Eastern Federal University, Ajax Bay 10, Russky Island, Vladivostok 690922, Russia.
Polina A SmirnovaDepartment of Chemistry and Materials, Institute of High Technologies and Advanced Materials, FEFU Campus, Far Eastern Federal University, Ajax Bay 10, Russky Island, Vladivostok 690922, Russia.ORCID 0000-0002-2627-5227
Natalia E GrammatikovaLaboratory of Chemical Transformation of Antibiotics, Gause Institute of New Antibiotics, Moscow 119021, Russia.ORCID 0000-0003-3508-231X
Elena B IsakovaLaboratory of Chemical Transformation of Antibiotics, Gause Institute of New Antibiotics, Moscow 119021, Russia.
Andrey E ShchekotikhinLaboratory of Chemical Transformation of Antibiotics, Gause Institute of New Antibiotics, Moscow 119021, Russia.ORCID 0000-0002-6595-0811
Olga N StyshovaDepartments of Biotechnology and Marine Natural Compounds Chemistry, G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch of The Russian Academy of Sciences, Vladivostok 690922, Russia.
Anna A KlimovichDepartments of Biotechnology and Marine Natural Compounds Chemistry, G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch of The Russian Academy of Sciences, Vladivostok 690922, Russia.ORCID 0000-0003-4477-4203
Aleksandr M PopovDepartments of Biotechnology and Marine Natural Compounds Chemistry, G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch of The Russian Academy of Sciences, Vladivostok 690922, Russia.

Funding

the Ministry of Science and Higher Education of the Russian Federation 075-03-2022-114/7 (project FZNS-2022-0014)
6 · The paper itself

Abstract

Fascaplysins form a group of marine natural products with unique cationic five-ring coplanar backbone. Native fascaplysin exhibits a broad spectrum of bioactivities, among which the cytotoxic activity has been the most investigated. Several fascaplysin derivatives have more selective biological effects and are promising as lead compounds. Thus, the introduction of a substituent at C-9 of fascaplysin leads to a strong increase in its antimicrobial properties. Here, a comparative assessment of the antimicrobial activity of synthetic analogs of the marine alkaloids 3-bromofascaplysin, 10-bromofascaplysin, and 3,10-dibromofascaplysin, along with some of their isomers and analogs, was carried out against a panel of Gram-positive bacteria in vitro. For the first time, a significant increase in the antimicrobial activity of fascaplysin was observed when a substituent was introduced at C-3. The introduction of two bromine atoms at C-2 and C-9 enhances the antimicrobial properties by 4 to 16 times, depending on the tested strain. Evaluation of the antimicrobial potential in vivo showed that fascaplysin and 3,10-dibromofascaplysin had comparable efficacy in the mouse staphylococcal sepsis model. Additionally, 3,10-dibromofascaplysin demonstrated a strong and reliable antitumor effect in vivo on the Ehrlich carcinoma inoculated subcutaneously, with a value of tumor growth inhibition by 49.2% 20 days after treatment. However, further studies on alternative chemical modifications of fascaplysin are needed to improve its chemotherapeutic properties.

Indexed as

AlkaloidsAnti-Bacterial AgentsAntineoplastic AgentsIndolesAnimalsAquatic OrganismsCarbolinesCarcinoma, Ehrlich TumorCell Line, TumorGram-Positive BacteriaHumansIndolizinesMiceMicrobial Sensitivity TestsQuaternary Ammonium CompoundsStructure-Activity RelationshipAlkaloidsAnti-Bacterial AgentsAntineoplastic AgentsCarbolinesfascaplysineIndolesIndolizinesQuaternary Ammonium Compounds3,10-dibromofascaplysinantibacterial activityantitumor efficacyfascaplysin derivatives

Identifiers

PMID39997192
PMCPMC11857626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.